BLOG

Brandon Ossont and Jennifer Lakritz share their first AALAS experiences, exploring scientific insights, networking, and professional growth in lab animal science.

Julie Forget reflects on the ACT Annual Meeting, highlighting cutting-edge toxicology research, gene therapy trends, and the strong sense of scientific community.

Altasciences conducted two drug-drug interaction studies to evaluate a novel cardiovascular therapy’s safety with clopidogrel and warfarin, ensuring safe co-administration.

Explore 30 years of CRO evolution, from preclinical roots to integrated, flexible partnerships—and how Altasciences is shaping the future of drug development.

See how Altasciences supported a sponsor’s 505(b)(2) submission with three pivotal studies, driving simulation, bioavailability, and dose-escalation, to deliver critical data.

Discover seven tips from expert toxicologist and consultant Robin Guy on tackling key challenges for in vitro NAMs studies, from data integrity to regulatory acceptance.

Toxicologist Mary Ellen Cosenza explains the FDA’s 2025 roadmap for phasing out animal testing and its implications for drug development and safety.